249 related articles for article (PubMed ID: 19933982)
1. IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide.
Dubbink HJ; Taal W; van Marion R; Kros JM; van Heuvel I; Bromberg JE; Zonnenberg BA; Zonnenberg CB; Postma TJ; Gijtenbeek JM; Boogerd W; Groenendijk FH; Smitt PA; Dinjens WN; van den Bent MJ
Neurology; 2009 Nov; 73(21):1792-5. PubMed ID: 19933982
[TBL] [Abstract][Full Text] [Related]
2. First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response.
Taal W; Dubbink HJ; Zonnenberg CB; Zonnenberg BA; Postma TJ; Gijtenbeek JM; Boogerd W; Groenendijk FH; Kros JM; Kouwenhoven MC; van Marion R; van Heuvel I; van der Holt B; Bromberg JE; Sillevis Smitt PA; Dinjens WN; van den Bent MJ;
Neuro Oncol; 2011 Feb; 13(2):235-41. PubMed ID: 21177338
[TBL] [Abstract][Full Text] [Related]
3. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.
Houillier C; Wang X; Kaloshi G; Mokhtari K; Guillevin R; Laffaire J; Paris S; Boisselier B; Idbaih A; Laigle-Donadey F; Hoang-Xuan K; Sanson M; Delattre JY
Neurology; 2010 Oct; 75(17):1560-6. PubMed ID: 20975057
[TBL] [Abstract][Full Text] [Related]
4. The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma.
Kizilbash SH; Giannini C; Voss JS; Decker PA; Jenkins RB; Hardie J; Laack NN; Parney IF; Uhm JH; Buckner JC
J Neurooncol; 2014 Oct; 120(1):85-93. PubMed ID: 24993250
[TBL] [Abstract][Full Text] [Related]
5. No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas.
Ahmadi R; Stockhammer F; Becker N; Hohlen K; Misch M; Christians A; Dictus C; Herold-Mende C; Capper D; Unterberg A; von Deimling A; Wick W; Hartmann C
J Neurooncol; 2012 Aug; 109(1):15-22. PubMed ID: 22528790
[TBL] [Abstract][Full Text] [Related]
6. IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy.
Minniti G; Scaringi C; Arcella A; Lanzetta G; Di Stefano D; Scarpino S; Bozzao A; Pace A; Villani V; Salvati M; Esposito V; Giangaspero F; Enrici RM
J Neurooncol; 2014 Jun; 118(2):377-383. PubMed ID: 24748470
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Baumert BG; Hegi ME; van den Bent MJ; von Deimling A; Gorlia T; Hoang-Xuan K; Brandes AA; Kantor G; Taphoorn MJB; Hassel MB; Hartmann C; Ryan G; Capper D; Kros JM; Kurscheid S; Wick W; Enting R; Reni M; Thiessen B; Dhermain F; Bromberg JE; Feuvret L; Reijneveld JC; Chinot O; Gijtenbeek JMM; Rossiter JP; Dif N; Balana C; Bravo-Marques J; Clement PM; Marosi C; Tzuk-Shina T; Nordal RA; Rees J; Lacombe D; Mason WP; Stupp R
Lancet Oncol; 2016 Nov; 17(11):1521-1532. PubMed ID: 27686946
[TBL] [Abstract][Full Text] [Related]
8. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma.
SongTao Q; Lei Y; Si G; YanQing D; HuiXia H; XueLin Z; LanXiao W; Fei Y
Cancer Sci; 2012 Feb; 103(2):269-73. PubMed ID: 22034964
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.
Li S; Chou AP; Chen W; Chen R; Deng Y; Phillips HS; Selfridge J; Zurayk M; Lou JJ; Everson RG; Wu KC; Faull KF; Cloughesy T; Liau LM; Lai A
Neuro Oncol; 2013 Jan; 15(1):57-68. PubMed ID: 23115158
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.
Wick W; Platten M; Meisner C; Felsberg J; Tabatabai G; Simon M; Nikkhah G; Papsdorf K; Steinbach JP; Sabel M; Combs SE; Vesper J; Braun C; Meixensberger J; Ketter R; Mayer-Steinacker R; Reifenberger G; Weller M;
Lancet Oncol; 2012 Jul; 13(7):707-15. PubMed ID: 22578793
[TBL] [Abstract][Full Text] [Related]
11. Estimation of the occurrence rates of
Cho U; Yang SH; Yoo C
J Int Med Res; 2021 Jun; 49(6):3000605211019258. PubMed ID: 34162262
[TBL] [Abstract][Full Text] [Related]
12. Temozolomide. A new option for high-grade astrocytomas.
Schwenka J; Ignoffo RJ
Cancer Pract; 2000; 8(6):311-3. PubMed ID: 11898150
[No Abstract] [Full Text] [Related]
13. IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom.
Stockhammer F; Misch M; Helms HJ; Lengler U; Prall F; von Deimling A; Hartmann C
Seizure; 2012 Apr; 21(3):194-7. PubMed ID: 22217666
[TBL] [Abstract][Full Text] [Related]
14. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Hartmann C; Meyer J; Balss J; Capper D; Mueller W; Christians A; Felsberg J; Wolter M; Mawrin C; Wick W; Weller M; Herold-Mende C; Unterberg A; Jeuken JW; Wesseling P; Reifenberger G; von Deimling A
Acta Neuropathol; 2009 Oct; 118(4):469-74. PubMed ID: 19554337
[TBL] [Abstract][Full Text] [Related]
15. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
[TBL] [Abstract][Full Text] [Related]
16. Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
Sipos L; Vitanovics D; Afra D
Ideggyogy Sz; 2004 Nov; 57(11-12):394-9. PubMed ID: 15662767
[TBL] [Abstract][Full Text] [Related]
17. NICE verdict on Temozolomide: where next?
Brada M
Br J Cancer; 2002 Feb; 86(4):499-500. PubMed ID: 11870526
[No Abstract] [Full Text] [Related]
18. Mutation analysis of IDH1 in paired gliomas revealed IDH1 mutation was not associated with malignant progression but predicted longer survival.
Yao Y; Chan AK; Qin ZY; Chen LC; Zhang X; Pang JC; Li HM; Wang Y; Mao Y; Ng HK; Zhou LF
PLoS One; 2013; 8(6):e67421. PubMed ID: 23840696
[TBL] [Abstract][Full Text] [Related]
19. Limited efficacy of temozolomide alone for astrocytoma, IDH-mutant, CNS WHO grades 2 or 3.
Weller J; Katzendobler S; Blobner J; Thiele F; Becker H; Quach S; Egensperger R; Niyazi M; Suchorska B; Thon N; Weller M; Tonn JC
J Neurooncol; 2022 Oct; 160(1):149-158. PubMed ID: 36112301
[TBL] [Abstract][Full Text] [Related]
20. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection.
Beiko J; Suki D; Hess KR; Fox BD; Cheung V; Cabral M; Shonka N; Gilbert MR; Sawaya R; Prabhu SS; Weinberg J; Lang FF; Aldape KD; Sulman EP; Rao G; McCutcheon IE; Cahill DP
Neuro Oncol; 2014 Jan; 16(1):81-91. PubMed ID: 24305719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
